Dr Laura C Rios Carrion, MD | |
137 Calle Vidal Felix, Hatillo, PR 00659-1817 | |
(787) 820-5579 | |
(787) 820-5579 |
Full Name | Dr Laura C Rios Carrion |
---|---|
Gender | Female |
Speciality | Obstetrics/gynecology |
Experience | 39 Years |
Location | 137 Calle Vidal Felix, Hatillo, Puerto Rico |
Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1013944768 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207V00000X | Obstetrics & Gynecology | 9584 (Puerto Rico) | Primary |
Mailing Address | Practice Location Address |
---|---|
Dr Laura C Rios Carrion, MD 114 Calle Turquesa, Urb Villa Luisa, Cabo Rojo, PR 00623-3629 Ph: (787) 820-5579 | Dr Laura C Rios Carrion, MD 137 Calle Vidal Felix, Hatillo, PR 00659-1817 Ph: (787) 820-5579 |
News Archive
Mayo Clinic and the Translational Genomics Research Institute are helping launch a national clinical trial that will apply the latest in precision medicine to treat advanced melanoma skin cancer.
Caring for someone with a serious illness stretches people spiritually and emotionally, often beyond what they might have thought possible.
A baffling condition Sudden Infant Death Syndrome (SIDS) that leads to the unexplained deaths of many infants worldwide may have been explained in new Australian research. The researchers monitored babies as they slept on their bellies and found that they have reduced blood pressure and an increased heart rates, compared with when they slept on their backs as recommended. This effect is seen more in babies aged two to three months, the age when babies are most at risk of SIDS.
A targeted molecular-imaging method under development at Rochester Institute of Technology could help detect early stages of prostate cancer and improve image-directed biopsies.
GenSpera, Inc. announced its intention to expand its Phase I safety trial to study G-202 in relapsed, refractory cancer patients to the Cancer Therapy and Research Center (CTRC) at The University of Texas Health Science Center at San Antonio in San Antonio, TX. The expansion is dependent upon a successful review of the clinical protocol by the Health Science Center Institutional Review Board (IRB). The company anticipates admitting the first patient at this site in the first quarter of 2011.
› Verified 7 days ago